It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Accelerating your discovery with our global chemistry expertise, tailored strategies, and collaboration that deliver candidate-quality molecules while you retain full control of your science.
One Team Across the Full Drug Discovery Chemistry Landscape
At Sygnature Discovery, we work as an extension of your team, combining global chemistry expertise, transparent collaboration and dedicated leadership to help your discoveries succeed. Our multidisciplinary teams bring deep experience across modalities and therapeutic areas, tailoring every strategy to your goals and timelines.
Our integrated chemistry teams combine medicinal, synthetic, process and high-throughput chemistry to deliver molecules that matter. From Lipinski-compliant small molecules to bRo5 compounds, PROTACs, induced-proximity therapeutics, and antibody–drug conjugates (ADCs), we apply scientific rigor and flexibility across therapeutic areas and delivery methods including CNS, oral, inhaled, topical and IV.
Every project is built around shared goals, open communication and scientific precision. With automation, AI-enhanced design and seamless scalability from milligram to kilogram, we help you overcome complexity and accelerate progress. This has resulted in over 60 preclinical and 38 clinical candidates shaped by our expertise and your vision.
Our Chemistry Solutions
Unmatched expertise. World-class capability. From milligram to kilogram, our chemists push boundaries to deliver solutions that truly move discovery forward.
Medicinal Chemistry
Reaching an optimal drug profile takes experience, efficiency, and insight. With Sygnature’s medicinal chemists guiding your program, you’ll navigate complexity, seize patent opportunities, and move confidently toward the clinic.
Innovation starts with synthesis. Our scientists rapidly design and deliver novel, patentable molecules using cutting-edge methods, high-throughput experimentation, and fast troubleshooting to accelerate your project from idea to impact.
Purification without limits. Our unique SFC platform delivers seamless separation from milligram to kilogram scale. Fully integrated with discovery workflows, it eliminates bottlenecks and accelerates your path to breakthrough.
Our NMR team works alongside our chemistry groups to provide high-quality structural data that supports confident decision-making. Using state-of-the-art instrumentation and rigorous analysis, we confirm identity and assess purity, while offering insights into molecular behavior such as conformation, where appropriate and solvent-dependent.
Speed meets creativity. Our high-throughput chemistry platform accelerates discovery through rapid, efficient synthesis of diverse libraries. Using curated monomer sets and deep expertise, we help you explore SAR and advance early-stage projects faster.
Embedding Direct‑to‑Biology methodologies into customer programs enables rapid, systematic expansion of SAR. This approach shortens the path to lead optimization and accelerates the delivery of candidate‑quality compounds.
Scale smarter. Our process chemists support your discovery team with route design, optimization, and troubleshooting—reducing risk and accelerating the path to IND with precision, efficiency, and scientific rigor.
Partnering with Sygnature Discovery gives you access to flexible collaboration models, and integrated capabilities that accelerate innovation, strengthen decisions, and drive candidate-quality outcomes.
Tailored to your goals
Customized chemistry programs aligned with your scientific vision, timelines, and budget — designed to accelerate progress toward key milestones and novel intellectual property creation.
Confidence through collaboration
Transparent communication, scientific ownership that stays with you, and dedicated project leadership ensure aligned decision-making and trusted, partnership-led progress.
Innovation that accelerates discovery
Our chemists translate the latest scientific advances into practical solutions, leveraging automation, high-throughput chemistry, and integrated data to deliver results faster and smarter.
From milligram to kilogram
Scale seamlessly from early discovery to development. Our synthetic and process chemistry expertise ensures robust, reproducible routes and smooth transition to CDMO or clinical manufacture.
No bottlenecks, no barriers
Integrated analytical and separation sciences keep your project moving – guaranteeing quality, purity, and timely delivery across every stage of the discovery journey.
Powered by experience
With thousands of publications and dozens of clinical candidates, our track record reflects a legacy of excellence and a commitment to advancing your success.
Why Choose Sygnature Discovery for Chemistry Support?
Your project deserves more than synthesis – It deserves partnership.
Collaboration, transparency, and scientific excellence define us. Our global chemistry teams combine innovation, AI-enhanced design, and seamless integration across disciplines—from milligram to kilogram scale. We communicate openly, anticipate challenges, and deliver solutions that move your discovery forward with speed, confidence, and measurable impact.
Meet our Team
Meet the experts leading our chemistry solutions. Discover the experience and innovation that drive success in drug discovery.
Mihiro brings over 25 years of experience in drug discovery, having worked across a diverse…
FAQs
Drug discovery chemistry covers the design and synthesis of new molecules with the potential to become medicines, spanning medicinal, synthetic, process, and analytical chemistry, each playing a distinct role from early design through to scale-up.
In short: medicinal chemistry designs which molecule to make, synthetic chemistry makes it, and process chemistry works out how to make it reliably at larger scale. Most programs need more than one, which is why our teams work together rather than in isolation.
Yes, each chemistry discipline above is available as a standalone service, so you can bring us in for one specific piece of work without committing to a wider program.
It depends on your stage: designing a new molecule points to medicinal chemistry, making a specific compound points to synthetic chemistry, and scaling up an existing route points to process chemistry. If you are not sure, get in touch and we will help you scope it.It depends on your stage: designing a new molecule points to medicinal chemistry, making a specific compound points to synthetic chemistry, and scaling up an existing route points to process chemistry. If you are not sure, get in touch and we will help you scope it.
Project start-up timelines vary depending on the scope of work, material availability and contractual/legal requirements. Once a work order is agreed and resources are allocated, project teams can typically begin work very quickly, with laboratory activities commencing as soon as any required building blocks have been received.
Our chemistry teams sit within Sygnature’s wider Integrated Drug Discovery workflow, working alongside biology, DMPK, and structural biology teams from the same site, so a compound doesn’t wait for a handoff between separate disciplines.
No. Sygnature runs no drug discovery programs of its own, so there is no risk of your chemical matter or program competing with our own commercial interests.
Due to the confidential nature of contract research, much of our work cannot be disclosed publicly. However, where permitted by our clients, our scientific contributions can be seen in published peer-reviewed journal articles, and selected case studies. These provide evidence of our expertise in compound design, synthesis, optimisation, and the delivery of high-quality discovery chemistry across a wide range of therapeutic areas and modalities.
Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Comprehensive target class solutions integrate advanced assays, structural biology, and medicinal chemistry to accelerate hit-to-lead and candidate selection.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
